CERUS CORP SEC Filings

CERUS CORP Chief Operating Officer Vivek K. Jayaraman reported an open-market sale of company stock. On May 1, 2026, he sold 16,667 shares of Cerus common stock at $3.00 per share. After this transaction, he directly holds 1,673,374 common shares. The filing notes the sale was executed pursuant to a Rule 10b5-1 trading plan, indicating it was carried out under a pre-arranged instruction rather than as a discretionary trade.

CERS (Form 144): The filing reports sales of restricted common stock by Richard J. Benjamin in multiple transactions during March 2026. The largest disclosed sale was 101,740 shares on 03/13/2026. Other reported disposals occurred on 03/09/2026 (40,426 shares), 03/06/2026 (24,235 shares) and 03/05/2026 (61,233 shares), with dollar amounts shown for each trade.

Company CERS reported proposed and recent sales of restricted common stock by an affiliate via a Form 144 notice. The filing lists restricted shares issuable on 03/12/2019 (7,355 shares) and 03/12/2021 (9,312 shares), and discloses recent dispositions of 165,200 shares on 03/13/2026 and 34,094 shares on 03/06/2026 with reported transaction values.

Cerus Corporation reported improved Q1 2026 results, with revenue growing and losses narrowing. Product revenue reached $53.7 million for the three months ended March 31, 2026, up from $43.2 million a year earlier, while government contract revenue was $6.2 million versus $5.6 million.

Loss from operations narrowed to $0.4 million, compared with $5.9 million in the prior-year quarter. Net loss attributable to Cerus was $1.6 million, or $0.01 per share, better than the $7.7 million net loss and $0.04 loss per share a year ago.

Cerus ended the quarter with $27.9 million in cash and cash equivalents, $52.6 million in short-term investments and $0.6 million of restricted cash. Debt totaled $84.9 million, including $52.4 million classified as current. Operating activities used $3.0 million of cash, while investing activities provided $9.9 million mainly from investment maturities.

Cerus Corporation reported strong first quarter 2026 results with higher revenue and a sharply lower net loss. Total revenue was $59.9 million, up 23% from $48.9 million a year earlier, driven by 24% product revenue growth to $53.7 million and 120% demand growth for INTERCEPT Fibrinogen Complex.

Product gross profit rose to $27.9 million, though product gross margin declined to 52.0% from 58.8% due to prior-year one-time benefits and current inflation, currency, and tariff impacts. Operating expenses fell 7% to $34.5 million, helping reduce net loss attributable to Cerus to $1.6 million, or $0.01 per share, from $7.7 million, or $0.04 per share.

The company generated non-GAAP adjusted EBITDA of $4.0 million versus $0.2 million a year earlier and ended March 31, 2026 with $80.4 million in cash, cash equivalents, and short-term investments. Cerus raised its 2026 product revenue guidance to a range of $227 million to $231 million, including IFC revenue between $22 million and $24 million, reflecting expected growth of 10% to 12% from 2025.

Cerus Corporation is asking stockholders to vote at its June 2, 2026 virtual annual meeting on four key items: electing two directors, expanding its 2024 Equity Incentive Plan by 10 million shares, approving executive pay on an advisory basis, and ratifying Ernst & Young LLP as auditor for 2026.

The proxy also highlights Cerus’ INTERCEPT Blood System franchise and 2025 results, including $206.1 million in product revenue, a narrowed GAAP net loss of $15.6 million, positive non-GAAP adjusted EBITDA of $9.5 million, and positive operating cash flow for a second year.

Cerus Corporation adopted a new executive severance plan that standardizes payouts for several senior officers if they are terminated without cause or resign for good reason, particularly around a change of control. The plan covers the CFO, COO, Chief Medical Officer and Chief Legal Officer.

Following a qualifying termination within 12 months after a change of control, participants receive a lump sum equal to 18 months of base salary and 1.5 times their target annual cash bonus, along with up to 18 months of paid COBRA premiums and full acceleration of all outstanding equity awards. For Vivek Jayaraman when serving as Chief Executive Officer, these change-of-control severance amounts increase to 24 months of base salary, two times target bonus and up to 24 months of COBRA.

Outside a change of control, the plan provides Mr. Green and Ms. Jensen (and Mr. Jayaraman while COO) with 12 months of salary continuation and up to 12 months of COBRA coverage. If Mr. Jayaraman is President and Chief Executive Officer at the time of a qualifying non-change-of-control termination, he also receives full equity acceleration and, for terminations after September 30, a prorated annual cash bonus based on his target opportunity and time worked.

Green Kevin Dennis reported acquisition or exercise transactions in this Form 4 filing.

CERUS CORP Chief Financial Officer Kevin Dennis Green received an equity grant of 200,000 shares of common stock. The award was made at a stated price of $0.00 per share as a stock-based compensation grant, not a market purchase or sale.

The grant was issued in the form of restricted stock units, each representing a contingent right to one share of Cerus common stock. These RSUs vest in full one year from the grant date, provided he continues serving the company through that vesting date. Following this grant, he directly holds 1,240,551 common shares.